Spectaire (SPEC) Competitors $0.05 0.00 (0.00%) (As of 11/12/2024 ET) Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesSEC FilingsShort InterestTrends SPEC vs. TBIO, THMO, OLITW, PRENW, QSIAW, SMAPW, TT, KEYS, FTV, and VLTOShould you be buying Spectaire stock or one of its competitors? The main competitors of Spectaire include Telesis Bio (TBIO), ThermoGenesis (THMO), OmniLit Acquisition (OLITW), Prenetics Global (PRENW), Quantum-Si (QSIAW), SportsMap Tech Acquisition (SMAPW), Trane Technologies (TT), Keysight Technologies (KEYS), Fortive (FTV), and Veralto (VLTO). These companies are all part of the "measuring and control equipment" industry. Spectaire vs. Telesis Bio ThermoGenesis OmniLit Acquisition Prenetics Global Quantum-Si SportsMap Tech Acquisition Trane Technologies Keysight Technologies Fortive Veralto Telesis Bio (NASDAQ:TBIO) and Spectaire (NASDAQ:SPEC) are both small-cap medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their dividends, media sentiment, valuation, risk, earnings, profitability, institutional ownership, analyst recommendations and community ranking. Which has more risk & volatility, TBIO or SPEC? Telesis Bio has a beta of 1.86, suggesting that its stock price is 86% more volatile than the S&P 500. Comparatively, Spectaire has a beta of -0.46, suggesting that its stock price is 146% less volatile than the S&P 500. Do institutionals & insiders hold more shares of TBIO or SPEC? 37.6% of Telesis Bio shares are held by institutional investors. Comparatively, 26.6% of Spectaire shares are held by institutional investors. 24.5% of Telesis Bio shares are held by insiders. Comparatively, 25.4% of Spectaire shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term. Does the MarketBeat Community favor TBIO or SPEC? Telesis Bio received 9 more outperform votes than Spectaire when rated by MarketBeat users. Likewise, 52.94% of users gave Telesis Bio an outperform vote while only 0.00% of users gave Spectaire an outperform vote. CompanyUnderperformOutperformTelesis BioOutperform Votes952.94% Underperform Votes847.06% SpectaireOutperform VotesNo VotesUnderperform Votes1100.00% Which has better valuation & earnings, TBIO or SPEC? Spectaire has lower revenue, but higher earnings than Telesis Bio. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioTelesis Bio$27.51M0.07-$47.72M-$28.20-0.04SpectaireN/AN/A$8.95MN/AN/A Do analysts prefer TBIO or SPEC? Spectaire has a consensus price target of $2.50, suggesting a potential upside of 4,850.50%. Given Spectaire's stronger consensus rating and higher probable upside, analysts plainly believe Spectaire is more favorable than Telesis Bio.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Telesis Bio 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00Spectaire 0 Sell rating(s) 1 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 2.00 Is TBIO or SPEC more profitable? Spectaire has a net margin of 0.00% compared to Telesis Bio's net margin of -336.59%. Spectaire's return on equity of -81.22% beat Telesis Bio's return on equity.Company Net Margins Return on Equity Return on Assets Telesis Bio-336.59% -359.32% -61.89% Spectaire N/A -81.22%304.57% Does the media prefer TBIO or SPEC? In the previous week, Telesis Bio had 1 more articles in the media than Spectaire. MarketBeat recorded 2 mentions for Telesis Bio and 1 mentions for Spectaire. Spectaire's average media sentiment score of 0.00 beat Telesis Bio's score of -0.63 indicating that Spectaire is being referred to more favorably in the news media. Company Overall Sentiment Telesis Bio Negative Spectaire Neutral SummarySpectaire beats Telesis Bio on 8 of the 14 factors compared between the two stocks. Ad WealthPressBreaking News: Tesla headed to $500…That headline hit late last night…and the rally has begun Which is why we want to urge you to go ahead and download Lance’s e-Book now outlining his bullish case for Tesla. So to claim your free digital copy today, simply follow this link and enter your email address. Get Spectaire News Delivered to You Automatically Sign up to receive the latest news and ratings for SPEC and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart SPEC vs. The Competition Export to ExcelMetricSpectaireMeasuring & controlling devices IndustryComputer SectorNASDAQ ExchangeMarket Cap$930,000.00$19.42B$24.19B$9.02BDividend YieldN/A2.91%2.73%4.01%P/E RatioN/A13.07225.7613.92Price / SalesN/A11.513,385.1097.63Price / Cash0.0815.9434.1137.13Price / Book-0.033.057.136.04Net Income$8.95M$505.69M$659.35M$225.15M7 Day PerformanceN/A-0.62%1.13%1.29%1 Month PerformanceN/A5.64%3.54%6.70%1 Year PerformanceN/A14.00%23.15%32.94% Spectaire Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)SPECSpectaireN/A$0.05flat$2.50+4,850.5%-97.7%$930,000.00N/A0.008Gap DownTBIOTelesis BioN/A$1.10-12.7%N/A-90.4%$1.95M$27.51M-0.04200Earnings ReportTHMOThermoGenesisN/A$0.00flatN/A-100.0%$5,000.00$9.44M0.0025OLITWOmniLit AcquisitionN/A$0.05flatN/A+36.8%$0.00N/A0.003Gap UpPRENWPrenetics GlobalN/A$0.01flatN/A-49.7%$0.00$22.66M0.001Short Interest ↑QSIAWQuantum-SiN/A$0.07flatN/A-75.2%$0.00$1.70M0.00159Short Interest ↓Gap DownSMAPWSportsMap Tech AcquisitionN/A$0.05+71.2%N/AN/A$0.00N/A0.00N/AGap UpTTTrane Technologies4.1712 of 5 stars$395.92+1.0%N/A+82.4%$89.09B$17.68B36.7340,000Positive NewsKEYSKeysight Technologies4.3186 of 5 stars$165.18+2.1%N/A+29.8%$28.67B$5.46B31.7714,900Upcoming EarningsShort Interest ↑FTVFortive4.8939 of 5 stars$74.01-0.4%N/A+14.0%$25.68B$6.07B29.4918,000Dividend AnnouncementAnalyst ForecastShort Interest ↓VLTOVeralto2.6034 of 5 stars$104.30+1.3%N/A+47.1%$25.47B$5.02B32.1916,000Positive News Related Companies and Tools Related Companies TBIO Alternatives THMO Alternatives OLITW Alternatives PRENW Alternatives QSIAW Alternatives SMAPW Alternatives TT Alternatives KEYS Alternatives FTV Alternatives VLTO Alternatives Top 10 Stock Comparisons Bank Stocks Artificial Intelligence Stocks Toy Stocks Growth Stocks Airline Stocks Chinese Stocks EV Charging Stocks Defense Stocks Lithium Stocks Pharmaceutical Stocks This page (NASDAQ:SPEC) was last updated on 11/13/2024 by MarketBeat.com Staff From Our PartnersBill Gates’s Next Big AI Bet: StargateIn February 2016… when almost nobody was talking about artificial intelligence…. I picked Nvidia as one of ...Brownstone Research | SponsoredTim Sykes’ Urgent Trade Alert: “Make this move now”WARNING: 80 Wall Street banks are gearing up for MASSIVE D.C. shock This $2 trillion D.C. shock is NOT abou...Timothy Sykes | SponsoredUnveiled: NVIDIA’s "Secret Royalty" ProgramDid you know that there's an investment that will give you the opportunity to collect "royalties" every time N...Behind the Markets | Sponsored24/7 Automated Profits in CryptoThe 4th quarter of 2024 is shaping up to be one of the most explosive periods for crypto in recent memory. But...Crypto Swap Profits | SponsoredYou just voted for a financial crisisI’d like to share with you my #1 high-conviction stock to buy before Inauguration Day… and details on the asse...Porter & Company | SponsoredTrump’s IRS Hands Massive ‘Victory Gift’ To 401K OwnersThe "Fake Media" has completely ignored Trump's genius "victory gift" to all America First patriots like you. ...Colonial Metals | SponsoredMusk’s new company could top a trillion?The investment legend who predicted the rise of Bitcoin, Facebook and streaming services like Netflix… Just...Paradigm Press | SponsoredTrump won. Buy this coin now.Juan Villaverde called the top and bottom of every crypto bull market since 2012. He believes Bitcoin will ...Weiss Ratings | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Spectaire Holdings Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Spectaire With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.